Skip to content
10-Q

Quarterly Report

Lexeo Therapeutics, Inc. LXEO

0000950170-25-068536

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Short Term Investments Q1 2025 · Mar 31, 2025 $70.92M
Short Term Investments Q1 2025 · Dec 31, 2024 $86.5M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $28.91M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $35.01M
Current Liabilities Q1 2025 · Mar 31, 2025 $30.82M
Current Liabilities Q1 2025 · Dec 31, 2024 $22.85M
Total Liabilities Q1 2025 · Mar 31, 2025 $37.58M
Total Liabilities Q1 2025 · Dec 31, 2024 $30.1M
Current Assets Q1 2025 · Mar 31, 2025 $105.27M
Current Assets Q1 2025 · Dec 31, 2024 $126.12M
Total Assets Q1 2025 · Mar 31, 2025 $125.69M
Total Assets Q1 2025 · Dec 31, 2024 $146.94M
Net Income Q1 2025 · Dec 31, 2024 −$98.3M
Net Income Q1 2025 · Mar 31, 2024 −$21.68M
Shares Diluted Q1 2025 · Mar 31, 2024 27.98M sh
Capex Q1 2025 · Mar 31, 2024 $185K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$14.87M
Stockholders Equity Q1 2025 · Mar 31, 2024 $182.95M
Stockholders Equity Q1 2025 · Dec 31, 2023 $113.54M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.77
Eps Basic Q1 2025 · Mar 31, 2024 −$0.77
Sga Expense Q1 2025 · Mar 31, 2024 $7.55M
Rd Expense Q1 2025 · Mar 31, 2024 $15.74M
Operating Income Q1 2025 · Mar 31, 2024 −$23.29M